Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Metastatic Renal Cell Carcinoma
NCT02774200Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in metastatic renal cell carcinoma (mRCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02774200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774200.